Q&A

Non-Viral Gene Modification For Ex-vivo Cell Therapy

Source: Lonza
DNA molecule-GettyImages-2148124383

In this interview, Ludger Altrogge, the Head of Transfection R&D at Lonza, elaborates on the advantages of non-viral transfection technologies, particularly in the context of CRISPR and transposon-based genetic modifications for cell and gene therapies. He highlights Lonza's Nucleofector® Technology, which is a cutting-edge method for enhancing the efficiency of genetic modifications.

Altrogge reviews the advantages of non-viral technologies, practical applications, and scalability and compliance.

access the Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Lonza